Celldex Therapeutics Inc. (CLDX) Plunges 11.39% on April 02
Celldex Therapeutics Inc. (CLDX) had a rough trading day for Tuesday April 02 as shares tumbled 11.39%, or a loss of $-0.58 per share, to close at $4.51. After opening the day at $4.71, shares of Celldex…
From the Equity Insider archive. This article dates from Apr 3, 2019 and is preserved as first published.
Celldex Therapeutics Inc. (CLDX) had a rough trading day for Tuesday April 02 as shares tumbled 11.39%, or a loss of $-0.58 per share, to close at $4.51. After opening the day at $4.71, shares of Celldex Therapeutics Inc. traded as high as $4.79 and as low as $4.46. Volume was 1.26 million shares over 4,274 trades, against an average daily volume of n/a shares and a total float of 12.44 million.
As a result of the decline, Celldex Therapeutics Inc. now has a market cap of $56.1 million. In the last year, shares of Celldex Therapeutics Inc. have traded between a range of $34.95 and $2.75, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer.
Celldex Therapeutics Inc. is based out of Hampton, NJ and has some 135 employees. Its CEO is Anthony S. Marucci.
